Current Urology Reports

, Volume 12, Issue 3, pp 188–196

Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?

  • Mohamed Ismail
  • Matthew Ferroni
  • Leonard G. Gomella
Article

DOI: 10.1007/s11934-011-0178-0

Cite this article as:
Ismail, M., Ferroni, M. & Gomella, L.G. Curr Urol Rep (2011) 12: 188. doi:10.1007/s11934-011-0178-0
  • 135 Downloads

Abstract

Androgen suppression therapy (AST) was first described in 1941 as a treatment of prostate cancer (PCa) and remains the mainstay of therapy in patients with hormone-naïve metastatic disease. It also is used in locally advanced or recurrent disease and in combination with radiation therapy in patients with higher-risk features. Several approaches to AST have been developed as a result of increased understanding of the pathways controlling testosterone production. Increased recognition of the side effects has resulted in strategies to minimize complications associated with AST. Attempts to reduce AST adverse effects include intermittent hormonal therapy and methods to reduce amount of intracellular androgens without reducing the circulating testosterone levels.

Keywords

Androgen suppression therapyHormonal therapyProstate cancerLuteinizing hormone–releasing hormoneLHRHLHRH agonistsLHRH antagonistsIntermittent hormonal therapyAntiandrogens

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Mohamed Ismail
    • 1
  • Matthew Ferroni
    • 2
  • Leonard G. Gomella
    • 2
  1. 1.Department of UrologyWilmington VA Medical CenterWilmingtonUSA
  2. 2.Department of Urology, Kimmel Cancer CenterThomas Jefferson UniversityPhiladelphiaUSA